Compared to Phentermine alone, Tirzepatide showed significant associations with reduced oculomotor binocular dysfunction (HR 0.44, 95% CI: 0.280.67, p = 1.3 10 4 ), visual issues and blindness (HR 0.51, 95% CI: 0.350.74, p = 2.8 10 4 ), dry eye disease (HR 0.46, 95% CI: 0.270.79, p = 0.004), ametropic accommodative dysfunction (HR 0.44, 95% CI: 0.280.68, p = 1.9 10 4 ), and visual disturbances (HR 0.45, 95% CI: 0.310.68, p = 7 10 5 )
If sleep disruption is a persistent issue, explore timing adjustments, evening eating habits, and sleep hygiene practices as primary interventions
Your provider will develop a personalized tirzepatide treatment plan
Many users report reduced appetite and cravings, helping support sustainable habits
Some people also notice fewer cravings or less food noise, making it easier to stay consistent with a structured plan